Major trial aims to stop silent strokes in heart patients before It's too late
NCT ID NCT07202897
Summary
This large study is testing if a common blood thinner (rivaroxaban) can prevent strokes and other serious complications in people with hypertrophic cardiomyopathy (HCM), a genetic heart condition. It focuses on over 500 patients who are in normal heart rhythm but show early signs of heart strain that predict a high risk for future stroke. The goal is to see if starting preventive medication early, before an irregular heartbeat develops, can save lives and improve quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.